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The complement system plays critical roles in development, homeostasis, and
regeneration in the central nervous system (CNS) throughout life; however, complement
dysregulation in the CNS can lead to damage and disease. Complement proteins,
regulators, and receptors are widely expressed throughout the CNS and, in many cases,
are upregulated in disease. Genetic and epidemiological studies, cerebrospinal fluid
(CSF) and plasma biomarker measurements and pathological analysis of post-mortem
tissues have all implicated complement in multiple CNS diseases including multiple
sclerosis (MS), neuromyelitis optica (NMO), neurotrauma, stroke, amyotrophic lateral
sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s
disease (HD). Given this body of evidence implicating complement in diverse brain
diseases, manipulating complement in the brain is an attractive prospect; however, the
blood-brain barrier (BBB), critical to protect the brain from potentially harmful agents in the
circulation, is also impermeable to current complement-targeting therapeutics, making
drug design much more challenging. For example, antibody therapeutics administered
systemically are essentially excluded from the brain. Recent protocols have utilized
“Trojan horse” techniques to transport therapeutics across the BBB or used osmotic
shock or ultrasound to temporarily disrupt the BBB. Most research to date exploring the
impact of complement inhibition on CNS diseases has been in animal models, and some
of these studies have generated convincing data; for example, in models of MS, NMO,
and stroke. There have been a few recent clinical trials of available anti-complement
drugs in CNS diseases associated with BBB impairment, for example the use of the
anti-C5 monoclonal antibody (mAb) eculizumab in NMO, but for most CNS diseases
there have been no human trials of anti-complement therapies. Here we will review
the evidence implicating complement in diverse CNS disorders, from acute, such as
traumatic brain or spine injury, to chronic, including demyelinating, neuroinflammatory,
and neurodegenerative diseases. We will discuss the particular problems of drug access
into the CNS and explore ways in which anti-complement therapies might be tailored for
CNS disease.
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INTRODUCTION
The Central Nervous System (CNS) as a
Distinct Environment
The CNS was, for a long time, considered an immunologically
privileged organ because the brain and spinal cord are protected
from circulating inflammagens by the BBB. The BBB is a
specialized membrane comprised of endothelial cells with tight
junctions, vascular pericytes and perivascular glia (Figure 1A),
FIGURE 1 | Schematic representation of cell types in the brain and their responses to injury. (A) Schematic representation of the cell types in the healthy brain.
(B) During CNS injury and disease the BBB is compromised. There is significant microgliosis and astrogliosis, characterized by glial cell proliferation, upregulation of
complement components, regulators and receptors, proinflammatory mediators, and active phagocytosis. Complement protein expression/deposition are increased
on neurons and oligodendrocytes tagging them for removal by phagocytosis and driving neurodegeneration and demyelination.
which cooperate to form a selectively permeable barrier,
protecting the CNS from fluctuating ion concentrations and
circulating neurotransmitters, macromolecules, large proteins
such as complement, and pathogens (1). However, isolation of
the CNS is not absolute and there are a number of pathways
by which systemic inflammation can be communicated to the
CNS [reviewed; (2)]. Indeed, the recent demonstration of a
CNS lymphatic system further undermines the concept of brain
immunological privilege (3).
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The healthy BBB forms early in development and restricts
the infiltration of circulating immune cells into the brain
parenchyma; hence, the dominant immune cells of the
brain are the resident macrophage population—microglia
(Figure 1B). This self-renewing (4), yolk sac-derived population
develops within the CNS (5–7) and differs in many respects
from macrophage populations found in the periphery (8–
10). Compared to tissue macrophages, microglia are relatively
“immune suppressed” due to expression of receptors for
soluble signals in the extracellular milieu, for example, β2
adrenergic receptor binding of noradrenaline (11, 12), and
signals delivered through direct contact with surrounding
neurons, including CD200R, CX3CR1 (13, 14). The downstream
signaling of such receptors suppresses the production of
proinflammatory mediators and encourages a neuroprotective
microglial phenotype. Resting microglia are relatively sessile,
ramified cells; their numerous highly motile protrusions
sample the entire brain every few hours (15, 16). Upon
stimulation, these protrusions are withdrawn to create ameboid
microglia that are migratory and upregulate expression of
proinflammatory mediators and activating receptors involved in
pattern recognition and phagocytosis (Figure 1B). This activated
phenotype, if not kept in check, can cause havoc in the vulnerable
CNS. More recently, it has been recognized that there are
brain region-specific subpopulations of microglia with different
responses to triggers and varying degrees of immune-vigilance
(17, 18). There also exist resident non-microglial populations in
the healthy brain including perivascular, meningeal and choroid
plexus macrophages, which are capable of responding to noxious
stimuli. In addition, during pathology blood borne macrophages
and other immune cells are recruited to the injured brain as a
result of increased BBB permeability. Astrocytes are a neglected
cell type, despite the fact that they comprise ∼70% of the cells in
the brain, where they form syncytial networks around neurons.
During health their primary role is homeostatic; they provide
neurons with energy and neurotrophic support, and buffer ion
and neurotransmitter concentrations [Reviewed elsewhere by
Sofroniew and Vinters (19)—Figure 1A]. During inflammation,
astrocytes demonstrate their immune-competence; they produce
proinflammatory cytokines, are capable of phagocytosis, and
can even present antigens to adaptive immune cells; however,
acquisition of these immune roles is often associated with loss
of homeostatic functions [(19)—Figure 1B].
Importantly for the subject matter of this review, there
is compelling evidence that, during inflammation, not only
microglia and astrocytes, but also neurons, oligodendrocytes,
and endothelial cells in the brain, can express complement
components, receptors, and regulators.
The Complement System
Complement is recognized as an important branch of the
innate immune system, providing the first line of defense
against microorganisms. As complement is the subject of
this issue, we will confine ourselves to a brief summary
(represented in Figure 2). Complement comprises multiple
recognition molecules that detect and bind target surfaces and
recruit a cascade of protease enzymes and substrates, resulting
in: (1) production of potent anaphylatoxins that attract and
activate phagocytes; (2) formation of the lytic membrane attack
complex (MAC); (3) target opsonization for phagocytosis and
destruction (Figure 2). Three activation pathways, classical,
lectin and alternative, converge on a common final pathway.
The classical pathway is initiated by the C1 complex binding
to antibody/antigen aggregates; the lectin pathway is triggered
by binding of mannose-binding lectin (MBL) or ficolins to
carbohydrate epitopes on targets; the alternative pathway is better
considered as an amplification loop that is engaged regardless of
the initial trigger. The activation pathways converge at the central
C3 and C5 convertases, which generate potent anaphylatoxins
C3a and C5a, C3b to opsonize surfaces facilitating phagocytosis
and C5b to initiate MAC formation. The complement pathway
mediates many of its effects through specific receptors on cells
and is tightly controlled by regulators present on cells and in
plasma, as discussed below (20).
The majority of complement proteins are predominantly
synthesized in the liver (21, 22); however, it is becoming
increasingly clear that complement proteins and their cognate
receptors and regulators are expressed throughout the CNS.Most
studies to date have utilized primary brain cell cultures and
relevant cell lines and have identified complement expression at
messenger RNA (mRNA) and/or protein level. Human primary
oligodendrocytes expressed mRNA for all the components of the
classical and terminal pathways and protein was detected for
most of these (23). Human oligodendrocyte cells (HOG cell line)
expressed the membrane complement regulators CD59, decay
accelerating factor (DAF) andmembrane cofactor protein (MCP)
and secreted C1-inhibitor (C1INH), Vitronectin and Clusterin,
whereas human astrocyte-derived cell lines expressed the same
membrane regulators and the important C3/C5 fragment
receptors complement receptor 1 (CR1) and C5a receptor (C5aR)
(24, 25). Cultured microglia from human post-mortem brain
(normal and Shy-Drager’s syndrome) constitutively expressed
mRNA for C1qB and C3 while C4 was expressed upon interferon
(IFN)-γ stimulation (26). C4, C9, C1q, FH, C1INH, C3, C6, and
Factor B (FB) were expressed in human neuronal cells in vitro
whereas primary rat cerebellar granule cells expressed mRNA
for C4, C1q, and C3 upon differentiation (27). Additionally,
complement expression can be upregulated in disease; for
example, C3, C1r and C1s expression was increased in primary
microglia and astrocyte cultures from post-mortem brain upon
exposure to cytokines associated with AD (28). Expression of
C1INH, C1s, C1q and C3 mRNA was detected in AD and control
brain extracts (29). Additionally, C1q, C3 and C4 gene expression
was reported in primary microglia from AD patients (30).
Cumulatively, the evidence suggests that nearly all complement
proteins, regulators, and receptors are expressed in the CNS, and
many are upregulated by inflammatory signals; it is therefore
likely that a functional complement system is present in the CNS
independent of peripheral complement.
Roles of Complement in CNS Development
Complement proteins are involved in both prenatal and
postnatal development of the healthy brain. In Xenopus embryos,
morpholino knockdown of C3a receptor (C3aR) or blocking
Frontiers in Immunology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 362
Carpanini et al. Complement Therapeutics in the CNS
FIGURE 2 | The complement pathway. The classical pathway is activated through antibody/antigen recognition by C1q in complex with C1r and C1s. The proteases
C1r and C1s cleave C4 and C2 to generate the C3 convertase C4b2a regulated by complement receptor 1 (CR1), C4 binding protein (C4BP), decay accelerating
factor (DAF), membrane cofactor protein (MCP), and factor I (FI). The lectin pathway is triggered by binding of mannose-binding lectin (MBL) or ficolins (FCN) to
carbohydrate epitopes on targets. The MBL-associated serine proteases (MASPs) then cleave C4 and C2 to generate the C3-convertase as in the classical pathway.
C1-inhibitor (C1INH) functions as a regulator to prevent excessive activation of both classical and lectin pathways. The alternative pathway is better considered as an
amplification loop. C3b binds factor B (FB) to form C3bB. FB is cleaved by Factor D (FD) to form the C3bBb C3-convertase stabilized by properdin (P). This process is
regulated by CR1, FI, factor H (FH), DAF and MCP. At this point the pathways converge—both C3-convertases cleave C3 to generate the anaphylatoxin C3a, and
more C3b that binds to form the C5-convertases (C4b2a3b and C3bBb3b) that cleave C5 into C5a and C5b. C3a and C5a are potent anaphylatoxins that act through
their respective receptors (C3aR, C5aR1, C5L2, and C5aR2) to recruit immune cells. C5b binds C6, C7, C8 (inhibited by vitronectin and clusterin) and multiple copies
of C9 (inhibited by CD59) to form the lytic membrane attack complex (MAC). C3b opsonizes targets for phagocytosis and B-cell activation; C3b decays to iC3b then
C3dg catalyzed by FI in the presence of cofactors (CR1, MCP, FH, C4BP).
antibody against C3a administered during neural tube formation
cause loss of neural crest cell organization, demonstrating a
role for C3a and its receptor in the migration of neural crest
cells (31). Central lectin pathway components Mannan-binding
lectin associated serine protease (MASP)-1 and MASP-2 are
highly expressed in the developing mouse brain with MASP
(and C3) knockout mice showing defects in neuronal migration
suggesting critical roles for complement activation in CNS
development (32).
Complement also plays key roles in postnatal brain
development. In humans and rodents, removal of redundant
connections by synaptic pruning during childhood and early
adult life is crucial for optimal brain function (33, 34). Using
the developing rodent visual system as a model for synaptic
pruning, it was shown that C1q and C3 (likely C3b/iC3b) localize
to, and tag, specific synapses in the dorsal lateral geniculate
nucleus (dLGN) for removal during development (35). C3
deficient (−/−) mice had improved hippocampal-dependent
learning and memory (36), and failed to show the age-associated
synapse loss observed in wild type animals (37), suggesting that
complement is detrimental to synapse health. However, in a
finding illustrating the dual nature of complement, C1q−/−,
C3−/−, and C4−/− mice all showed defects in synaptic pruning
in the CNS that, in the former, associated with increased
susceptibility to epilepsy (35, 38, 39). Furthermore, the C3b/iC3b
receptor complement receptor 3 (CR3) is expressed on the
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surface of microglia and CR3−/− mice showed defects in
microglial engulfment of synapses, suggesting a collaboration
between complement and microglia in synapse elimination (40).
Taken together, these data highlight a critical involvement of
the classical pathway in refinement of synapse networks during
normal development.
Complement and Neuroinflammation in
CNS Disorders—Identifying
Druggable Targets
As has been thoroughly reviewed elsewhere (41), inflammation
in general and neuroinflammation in particular, is a double-
edged sword, evolved to fight infection and restore or maintain
homeostasis but, when uncontrolled, capable of wreaking havoc.
The aim is therefore not to stop inflammation but encourage a
protective rather than destructive profile and prompt resolution
of inflammation. Given the important roles of complement
in the developing brain, in defense against infection and
in maintaining homeostasis, there may be situations where
enhancing complement activity may be of benefit; however, in
the context of CNS pathology, complement dysregulation leading
to over-activation, has deleterious consequences and contributes
to neuroinflammation.
Thus, the complement system offers an attractive drug target
for these diseases that are currently without effective therapies.
Drugging the complement pathway in the periphery is well
researched and this knowledge could potentially be extrapolated
to the CNS.
CNS disorders can be divided into acute, for example
traumatic injury and stroke, and chronic, for example,
demyelinating and neurodegenerative disorders, dependent
on the causation, severity and duration. In the sections below,
we will present evidence for the role of complement in both
acute and chronic neurological disorders. We will not include
stroke because this is discussed elsewhere in this issue and will
also omit detailed discussion of the demyelinating diseases
MS and NMO for brevity and because these have been well
reviewed elsewhere (42, 43). Our overall aim is to provide
insight into how complement therapeutics might impact these
problematic diseases.
COMPLEMENT PROTEINS IN ACUTE
NEUROLOGICAL
DISORDERS—TRAUMATIC BRAIN AND
SPINAL CORD INJURY
Traumatic Brain Injury (TBI)
TBI is classified as an injury to the brain due to trauma to the
head via an external force; this can occur as a result of road traffic
accidents, falls, sporting injuries or assaults; consequently, TBI
is the major cause of brain injury and death in young adults
in the Western world. TBI can cause diffuse or focal damage
to the brain tissue and blood vessels depending on the type
of injury. Subsequent to this primary injury, the BBB becomes
compromised and there is a huge influx of cells, inflammatory
mediators and plasma proteins, including complement proteins,
that drive the delayed secondary inflammation, which is the
major determinant of clinical outcome and thus recovery and
survival (44). Human post-mortem TBI studies have shown
increased expression of C3 and FB in brain and CSF (45) and
both axonal and astrocytic expression of Clusterin (46). Increased
soluble C5b-9 (terminal complement complex; TCC) levels were
found in CSF after TBI, positively correlating with the degree of
BBB damage (47), and further increased in response to secondary
insults (oxygen deprivation/seizures) (48).
A wide array of TBI models are utilized in animal research,
including cryoinjury, controlled cortical impact and standardized
weight drop [models are reviewed elsewhere; (44)]. Increased
C3 deposition, Clusterin and MAC deposition were observed
alongside increased microglial and astrocytic activation markers
after cortical contusion in the rat (49). Serum proteomics
in Sprague-Dawley rats after “severe” deep cortical impact
reported increased C9 and FB within the first few days after
TBI (50). Complement deficient mouse models have been
used to identify the impact of complement on neuropathology
after TBI (Table 1). C3−/− and C5−/− mice showed reduced
neutrophil extravasation upon traumatic brain cryoinjury (51);
C4−/− mice, but not C3−/− or C1q−/− mice showed reduced
motor deficits and tissue damage following controlled cortical
impact (52). In the same TBI model, CR2/CR1−/− mice showed
improved outcome with decreased mortality, neuronal cell death,
C3 deposition, astrogliosis, and microgliosis (53). FB−/− mice
also showed reduced cell death in TBI with increased anti-
apoptotic and decreased pro-apoptotic markers (54). In one
study, MBL−/− mice were protected from neurological injury
following TBI (70); in contrast, another reported that MBL−/−
mice showed increased levels of degenerating neurons in the
hippocampus CA3 region and impaired performance in non-
spatial learning tasks (71). Despite several such inconsistencies,
the studies to date suggest that deficiencies of individual
complement proteins of the classical, alternative or terminal
pathway improves outcome after TBI. However, all these studies
used rodent models where the relevant protein is knocked
out systemically from embryogenesis. Thus, it is important
to identify whether anti-complement therapeutics administered
immediately post-injury can have a similar beneficial effect,
and to define the “therapeutic window of opportunity” for
intervention post-injury.
The majority of therapeutic studies in TBI models have
focused on targeting the C3 convertase as a central player
of all three activation pathways (Table 2). Administration of
soluble CR1 (sCR1) pre- and post-TBI in rats reduced neutrophil
accumulation in the injured brain (72). Administration of
vaccinia virus complement control protein (VCP), an inhibitor
of C3 activation, improved performance in spatial memory
tasks after TBI (77). In mice, systemic inhibition of C3 via
administration of Crry-Ig (recombinant chimeric Complement
receptor 1-related protein Y (Crry) fused to mouse IgG1 Fc) 1
and 24 h post-TBI ameliorated neuronal damage in hippocampus
and improved neurological outcome (87). Transgenic mice
expressing soluble Crry (sCrry) specifically in astrocytes were
protected in closed head injury TBI, with reduced C3 deposition,
decreased BBB damage and improved neurological scores (88).
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TABLE 1 | Consequence of complement deficiency on outcome of
neurodegenerative disease.
Model Deficiency Consequence Reference
TBI Traumatic brain
cryoinjury
C3 Reduced pathology (51)
Controlled cortical
impact
C3 No effect (52)
Controlled cortical
impact
C4 Improved function (52)
Traumatic brain
cryoinjury
C5 Reduced pathology (51)
Closed head injury CR2 Improved function (53)
Controlled cortical
impact
C1q No effect (52)
Closed head injury FB Reduced pathology (54)
SCI T9 contusion C1q Improved function (55)
Contusion induced
injury
FB Improved function (56)
Weight drop C3 Improved function (57)
Contusion injury C5a Improved function (58)
Contusion induced
injury
CD59 Impaired recovery,
increased injury
(56)
AD Tg2576 C1q Ameliorates synapse
loss
(59)
oAβ injection C1q Ameliorates synapse
loss
(60)
APP/PS1 C3 Ameliorates synapse
loss
(60)
J20 APP C3 Exacerbated pathology (61)
oAβ injection CR3 Ameliorates synapse
loss
(60)
APP/PS1 C3 Improved function (62)
ALS SOD1G37R C1q No effect (63)
SOD1G37R C3 No effect (63)
SOD1G37R C4 No effect (64)
SOD1G37R C5aR1 Extended survival (65)
HD R6/2 C3 No effect (66)
PD MPTP induction of PD C3 No effect (67)
MPTP induction of PD C1q No effect (68)
Paraquat/maneb
induction of PD
CR3 Reduced dopaminergic
neurodegeneration
(69)
TBI, Traumatic brain injury; SCI, spinal cord injury; AD, Alzheimer’s disease; ALS,
Amyotrophic lateral sclerosis; PD, Parkinson’s disease; HD, Huntington’s disease.
Intravenous (iv) administration of C1INH 10min post TBI
reduced cognitive deficits and brain lesion size (89) and, in
a separate study, improved motor scores, reduced cognitive
dysfunction and reduced injury volume (90). Alternative
pathway inhibition with systemically administered anti-FB
reduced neuronal damage after TBI in mice (73). Lectin pathway
inhibition using a multivalent MBL ligand improved functional
and pathological outcome measures in a mouse TBI model
(76). Terminal pathway inhibition using either the tick-derived
C5 inhibitor OmCI or C6 antisense oligonucleotide decreased
neuropathology and promoted recovery in severe closed head
injury (74), and targeted inhibition of the terminal pathway
using a CD59-CRIg hybrid that localized to areas of C3b/iC3b
deposition in the injured brain was strongly neuroprotective in
the same model (75). Recently, to determine which component
or pathway of complement should be targeted for most efficient
protection in TBI, three hybrid proteins, all containing CR2 to
target to areas of complement activation, CR2-CD59 (inhibition
of MAC), CR2-Crry (all complement pathways) and CR2-FH
(alternative pathway), were compared; the latter two were most
effective, demonstrating important roles for early activation
products, both opsonins and anaphylatoxins (91).
Spinal Cord Injury (SCI)
SCI can be caused by sudden traumatic insults that crush or sever
the cord, or non-traumatic injuries, for instance, triggered by
cancer, arthritis or infection and usually compressing sections
of cord; here we will restrict discussion to traumatic causes.
SCI results in dysfunction and sometimes complete loss of
function below the lesion site. Symptoms are often life-long
and, since SCI is most common in under-30s, is associated
with huge personal and health-care costs (https://www.spinal-
research.org/). In traumatic SCI the primary pathology is caused
by a mechanical force directly damaging the neural tissue—
this primary insult is difficult to protect against. However,
post-injury inflammation, with infiltration of immune cells and
production of pro-inflammatory mediators, results in secondary
pathology in adjacent areas characterized by oedema, ischemia,
and excitotoxicity (92). There is considerable blood-spinal cord
barrier (BSCB) damage and resultant inflammation in this
secondary phase; despite this, studies of complement in SCI are
scarce. Early human studies showed elevated C3, C4, and C5
levels in plasma of patients post-SCI suggestive of an acute phase
response (93). As with TBI, rodent models of SCI vary widely;
many different approaches to inducing injury have been taken,
including weight drop, contusion, compression, laceration, and
chemical injection. Complement proteins were deposited at sites
of SCI in rodents; C1q, FB, C4, and TCC expression all increased
at and around the injury within 24-h post-SCI and remained
high up to 6 weeks (94, 95), and FH and Clusterin were elevated
in lesioned neurons and oligodendrocytes (96). In a less severe
weight-drop contusion SCI mouse model, C3 (likely C3b/iC3b)
was deposited in white matter at the site of injury at 4-h and
more widely in adjacent white and grey matter at 12- and 24-h,
returning to baseline by 3 days post-injury (57).
C3−/− mice were significantly protected in contusion-
induced SCI with reduced lesion size, necrosis, demyelination,
and neutrophil infiltration, improved locomotor score and
accelerated recovery (57); C1q−/− mice showed decreased
lesion volume and improvements in locomotion and fine
motor control compared to controls in the same model (55).
Mice deficient in FB subjected to contusion SCI showed
accelerated recovery of locomotion, marked improvements
in macroscopic tissue integrity, and reduced demyelination,
C3 and C9 deposition and infiltration of neutrophils and
macrophages compared to controls (56), while mice deficient
in the terminal pathway inhibitor CD59 showed increased
pathology with loss of myelin structure, scarring and vacuolation,
hemorrhage, neutrophil and macrophage infiltration, and TCC
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TABLE 2 | Consequence of pharmacological complement inhibition on outcome of neurodegenerative disease.
Model Drug Timing Consequence References
TBI Weight drop sCR1 2h and 2min prior and 2 h post Decreased neutrophil accumulation (72)
Weight drop Anti-FB 1 and 24 h post Decreased tissue damage (73)
Closed head OmCI Immediately prior, 15 and 30min post Improved function, reduced pathology (74)
Closed head C6 α-sense oligoNT 6 days prior for 4 days Improved function (74)
Cryoinjury AcF Immediately prior Decreased neutrophil extravasation (51)
Closed head CD59-2a-CRIg 30min and 24 h post Improved function (75)
Cortical impact Polyman9 10min post Improved function, reduced pathology (76)
Lateral fluid percussion VCP 15min post Improved function but not neuropathology (77)
SCI Weight drop sCR1 1h post and daily Reduced degeneration (78)
Mild impact VCP Immediately post Improved function and reduced pathology (79)
Pneumatic impact C1inh 2 h post injury Improved function (80)
Contusion Anti-FB 1 and 12 h post injury Improved function (56)
Compression PMX53 45min pre and 24 h post Improved function (58)
Contusion PMX205 14 days post Detrimental for functional recovery (81)
Weight drop CR2-Crry 1 h post Improved function (57)
AD Tg2576, 3xTg PMX205 After plaques for 2–3 mo 2x weekly Reduction in fAβ deposits and activated glia (82)
APP/TTA SB290157 3x week for 5 weeks from 7.25 mo Reduction in Aβ deposits (83)
Oligo Aβ ANX-M1 17 and 2min pre and 24 and 48 h post Prevented synapse loss and impairment of LTP (60)
ALS SOD1G93A rat PMX205 P28 and P70 Improved function (84)
hSOD1G93A ms PMX205 P35 (pre) and P31 (post) Improved function (85)
HD 3-NP rats PMX53 2 days prior Improved function (86)
3-NP rats PMX205 2 days prior and 2 days post Improved function (86)
TBI, Traumatic brain injury; SCI, spinal cord injury; AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; PD, Parkinson’s disease; HD, Huntington’s disease.
deposition (56). C5aR−/− mice showed acute but not long-
term improvements in functional recovery (97). In vitro studies
showed that C1q-treatment increased cortical neurite length
on myelin by inhibition of growth cone repulsion by myelin
associated glycoprotein (MAG); however, comparison of C1q KO
and C1q WT mice in a peripheral conditioning lesion model
of SCI showed no differences in axon length, lesion volume or
scarring, although C1q deficiency was associated with increased
axonal turning (98).
There are currently no proven therapies for SCI, unsurprising
given the many obstacles in promoting re-wiring of axons and
remyelination. Preventing or reducing the inflammation-driven
secondary phase offers opportunity; indeed, methylprednisolone
is the only currently available treatment though its effectiveness
is unclear (99–101). There have been a few studies of anti-
complement agents in SCI rodent models and the majority
of these have utilized iv administration, possible because of
BSCB disruption post-injury. Injection of the C3 convertase
inhibitor VCP into the injured spinal cord in a rat SCI model,
restored spinal cord tissue integrity, reduced macrophage
and microglial activation and improved acute motor deficits
(79, 102); iv administration of recombinant sCR1 in mice
1 h post-SCI and daily thereafter reduced neuron swelling,
degeneration, necrosis and neutrophil infiltration and improved
recovery (78); iv C1INH 2-h post-SCI in rats improved motor
recovery, reduced lesion volume and leukocyte infiltration (80).
Alternative pathway inhibition with iv anti-FB mAb accelerated
recovery and reduced lesion size in the same model (56). In
a contusion SCI mouse model, iv administered CR2-Crry
localized to the lesion site, improved locomotor deficits and
reduced necrosis, demyelination, and neutrophil infiltration
(57); because CR2-Crry targets specifically areas of pathology,
it is bioavailable in the SCI when given at a dose that does not
influence circulating complement activity, reducing the risk of
infections and other undesirable effects of systemic complement
inhibition. Another strategy to reduce infection risk is to target
C5a, a potent chemoattractant, or its receptor C5aR1 (CD88), a
G protein-coupled receptor (GPCR) expressed on granulocytes
monocytes/macrophages peripherally and on astrocytes and
microglia (and at low level neurons and oligodendrocytes) in
CNS (103, 104). Two small cyclic peptide C5aR1 antagonists
PMX53 and PMX205 (86, 105) have been tested in SCI models;
iv administration of PMX53 improved functional recovery,
and reduced macrophage/microglial numbers, expression of
pro-inflammatory cytokines IL-1β and TNF-α and astrogliosis in
mice compared with controls (58). In a rat SCI model, the impact
of PMX205 administration was dependent on timing post-injury
and was linked to the sequence of immune cell recruitment
to the site; whereas early administration accelerated recovery,
late administration inhibited the macrophage/microglial
response and slowed functional recovery and re-myelination
following injury, further emphasizing the importance of
timing interventions (81). Mice treated with C5aR antagonist
[hydrocinnamate—(OpdChaWR)] showed acute but not long
term improvements in functional recovery (97). Additionally,
bone marrow chimeric mice lacking peripheral but not central
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C5aR showed no differences from control mice. Together these
data suggest an initially detrimental role of C5aR followed
by a delayed neuroprotective role, likely mediated by CNS
resident cells.
Taken together, these studies indicate that inhibition of
classical/lectin and/or alternative pathways or specific effectors
like C5a can be efficacious in SCI. Timing of interventions
may be crucial to avoid impacting beneficial clearance roles of
complement. Terminal pathway inhibition has not been tested
in the models but the impact of CD59 deficiency noted above
suggests that this is a viable target.
COMPLEMENT PROTEINS IN CHRONIC
NEUROLOGICAL
DISORDERS—DEMYELINATION AND
NEURODEGENERATION
Inflammation was noted early as a feature of chronic brain
disease; indeed, astrogliosis andmicrogliosis were included in the
original descriptions of AD by Alois Alzheimer over a century
ago. Despite this, a classification divide emerged with diseases
like MS considered inflammatory while diseases like AD were
considered degenerative. The artificial nature of this divide has
become clear in recent years with the realization that there are
many shared features. The evidence implicating inflammation
as a driver of pathology in chronic neurodegenerative diseases
is now substantial and includes genetic studies identifying
inflammatory risk genes (106), clinical studies demonstrating
that long-term treatment with non-steroidal anti-inflammatory
drugs (NSAIDs) is protective in humans (107) and mouse
models (108) and the observation that systemic infections and
inflammation increase the risk and/or rate of progression of
dementia (109–111). Complement, the focus of this review,
goes hand-in-hand with inflammation and represents a potential
driver of chronic CNS diseases.
Alzheimer’s Disease (AD)
AD is the leading cause of dementia affecting almost 50
million people worldwide, a number projected to increase
to 150 million by 2050 (https://www.alz.co.uk/research/
statistics). AD is characterized by two hallmark pathologies;
amyloid-β (Aβ) plaques and neurofibrillary tangles comprising
hyperphosphorylated tau. Recent studies have implicated
complement in AD pathogenesis. Genome wide association
studies identified single nucleotide polymorphisms (SNPs)
associated with risk of late-onset AD in genes encoding
complement proteins Clusterin (CLU) and CR1 (CR1)
(106, 112, 113). Biomarker studies have identified complement
proteins and activation products in plasma and/or CSF that
distinguish AD from controls and predict risk of progression to
AD (114–117). Immunohistochemistry (IHC) of post-mortem
AD brain revealed complement proteins and activation products
decorating plaques and tangles. In particular, classical pathway
proteins C1q, C3, and C4 co-localized with amyloid fibrils,
Aβ deposits and neurofibrillary tangles, notably in temporal
cortex, amygdala, and hippocampus, in AD brain (118–120). The
terminal pathway activation marker TCC was abundant in AD
cortex in association with aggregated Aβ, neurofibrillary tangles
and neuropil threads (121). Cells expressing C5a receptors
C5aR1 and C5L2 were associated with neurofibrillary tangles,
neuropil threads, and dystrophic neurites in AD plaques in
hippocampus and frontal cortex (122). A weakness of these
IHC studies is that they are performed on post-mortem brain,
inevitably end-stage disease, and do not provide insight into
early disease or disease progression. A large-scale microarray
study of young, healthy old and AD brains identified marked
changes in complement expression with ageing, and elevated
expression of C4A, C4B, C3aR1, C5aR1, CFHR1, and CLU in
AD compared to age-matched controls; C1q binding protein
(C1qBP) expression decreased in AD (123). Increased C1q
expression in brain with ageing (healthy or AD) has been
robustly replicated (59, 124, 125).
Mechanisms of complement activation in the AD brain
have been studied in vitro and in animal models. Aβ fibrils
activate and consume complement classical and alternative
pathways in vitro and generate C3a, C5a, and TCC (119,
126). C5a administration resulted in death of primary mouse
neurons in culture; this could be blocked by addition of
C5aR1 antagonist PMX53, demonstrating that C5a (acting via
C5aR1) is sufficient to induce neuronal cell death in vitro (127).
Animal models have underpinned the majority of research into
roles and mechanisms of complement in AD. Most mouse
models mimic the rare early-onset forms of AD in which
single gene mutations have been identified rather than the
common polygenic late onset AD, and thus individually mimic
only certain aspects of the disease; it is therefore unsurprising
that different models yield different and often contradictory
results. Despite these reservations, these mouse models have
aided understanding of AD pathology. Broadly, models can
be divided into three groups: Aβ pathology; Tau pathology;
both. These mouse models recapitulate many of the pathologies
found in AD brain; for example, in the PS/APP model fibrillar
Aβ plaques form and C1q localizes to these plaques (128).
Back-crossing AD mouse models onto complement deficiencies
has been used to determine the role of complement in the
pathophysiology of AD (Table 1). Deficiency of C1q (classical
pathway) in Tg2576 (Aβ pathology) mice reduced glial activation
and synaptic loss without influencing Aβ load compared with
controls (59). Genetic deletion of C1q, C3 or CR3, all of which
are required for effective opsonization and phagocytosis of
synapses, reduced microglial numbers and synapse loss when
crossed to two different Aβ models (J20 and APP/PS1); further,
when Aβ fibrils were injected directly into brain, C1q deficiency
protected from toxicity (60). In contrast, C1q deficiency in
the 3xTG model exacerbated neurodegeneration because of a
loss of C1q-triggered expression of neuronal survival pathways
(129). Others showed that C3 deficiency improved performance
on learning and memory tests and decreased microglia and
astrocyte number associated with plaques in an Aβ model
(APP/PS1) (62); in contrast, C3 deficiency was associated
with increased amyloid burden, decreased neuronal staining
and activated glia in the J20 (Aβ) model (61). Despite the
evidence noted above that Tau pathology is associated with
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complement, there was a dearth of studies in Tau models;
two recent publications have changed this. Administration of
blocking anti-C1q antibodies in a mouse Tau model (P301S)
inhibited microglial synapse loss and rescued synapse density
(130), while C3aR deletion attenuated neuroinflammation and
reduced synaptic deficits and neurodegeneration in the PS19
Tau model (131).
As is clear from the anti-C1q experiment described above,
mouse models also offer a way to test in vivo the impact
of complement therapeutics on disease (Table 2). The C5aR1
antagonist PMX205 decreased amyloid and tau deposits, reduced
activated glia and improved cognition in two Aβmodels (Tg2576
and 3xTg) (82). Levels of C1q and C3 were unchanged upon
PMX205 treatment, suggesting that their physiological functions
are preserved. As noted above, blocking antibody against C1q
[(ANX-M1/ANX005); Annexon Biosciences] protected from
synapse loss in Aβ models and reduced toxicity of Aβ fibrils
injected into the lateral ventricles (60); this agent showed no
toxicity, even at high doses (200 mg/kg) and has proceeded
to clinical trials (132). A note of caution in the use of anti-
complement agents comes from a study of C3 inhibitor sCrry
administered to an Aβ model (hAPP × TGFβ1) which resulted
in increased Aβ deposition and neuronal degeneration (133).
The evidence—genetic, clinical, and from models—
implicating complement as a driver of pathology in AD is
compelling. A complicating factor is that complement may also
have protective roles in clearing debris in early disease. Improved
understanding of the time course of complement involvement
may identify therapeutic windows where complement inhibitors
will improve outcome.
Amyotrophic Lateral Sclerosis (ALS)
ALS, also known as Lou Ghering’s disease, is an adult onset
neurodegenerative disease, usually fatal within 2–5 years of onset
(134). ALS is caused by progressive loss of upper and lower (α)
motor neurons (135), resulting in denervation of neuromuscular
junctions in the peripheral nervous system, progressive muscle
weakness, atrophy, spasticity, respiratory failure, and ultimately
paralysis and death. Approximately 90% of ALS cases are
sporadic and 10% familial. Causative missense point mutations
have been identified in superoxide dismutase (SOD1), TAR DNA
binding protein (TDP-43), fused-in-sarcoma-protein (FUS), and
chromosome 9 open reading frame 72 (C9orf72). The only
currently available treatment for ALS is Riluzole, an ion channel
blocker and inhibitor of glutamate release which modestly
increases survival (136, 137).
Neuroinflammation is a consistent feature of ALS with
abundant reactive microglia and astrocytes and T-cell infiltration
observed (138). IHC identified increased C1q protein in motor
cortex and spinal cord of ALS post-mortem tissue; C3 activation
fragments and TCCwere also demonstrated in areas of pathology
(139, 140). C3c labeled astrocyte-like cells in the former study
whereas C1q and C3d co-localized with neurons, astrocytes and
microglia, and TCC primarily microglia, in the latter. Others
described C4d and TCC staining of degenerating neurons and
glia in ALS motor cortex and spinal cord (141) and C5aR1
upregulation in areas of pathology (142). C3d and C4d were also
found on oligodendroglia and degenerating neurites, surrounded
by CR4-positive microglia, in spinal cord and motor cortex
(141, 143). C1q, C3, and TCC were present on motor end-plates
in intercostal muscles in ALS donors even early in the disease
process (144); DAF and CD59 were upregulated at the end-
plates, perhaps reflecting a response to complement activation
and TCC/MAC deposition. TCC immunoreactivity at end-plates
negatively correlated with α-bungarotoxin staining, implicating
TCC/MAC in loss of end-plates (144). In myasthenia gravis, end-
plate destruction is dependent on complement activation and
MAC formation (145), supporting a causative role in ALS.
The source of complement in ALS pathology is unclear; the
BBB is disrupted in the disease (146); however, local biosynthesis
likely also contributes. In situ hybridization demonstrated
upregulated C1qb and CLU mRNA in areas most affected by
neurodegeneration (147); more recently, increased C1q and
C4 expression by glial cells was demonstrated in ALS cord
white matter (140) indicating a local source of complement.
Complement expression positively associated with increased
infiltration of dendritic cells and CD8+ T-lymphocytes from
the periphery (140, 141). Biomarkers also implicate complement.
Complement activation products C3c and C4d were present in
CSF and correlated with disease severity scores (148–150). Levels
of C5a and TCC were significantly elevated in ALS plasma, and
leukocytes from ALS patients had increased surface (C5aR1-
bound) C5a (151). These biomarker findings strongly support
a role for complement dysregulation in ALS patients; however,
the nature and location of complement protein deposition in
different studies was contradictory, perhaps due to differences in
disease stage or comorbidities.
Numerous rodent models of ALS have been generated
based on known causative mutations in SOD1, responsible for
∼10% of familial ALS. Rodents over-expressing human mutant
SOD1G93A recapitulate key neuropathological and functional
hallmarks of ALS, characterized by lumbar motor neuron
loss which correlates with progressive motor deficits and
ultimately paralysis, and by inflammatory changes including
robust astrogliosis, microgliosis, and BBB-disruption (152–
154). Complement dysregulation is apparent from increased
expression and deposition of C1q, C4, FB, C3 activation products
and TCC, increased expression of C5aR1, and reduced expression
of complement regulators DAF and CD59 (64, 84, 144, 154–
156). Complement deposition has also been observed in sciatic
nerves (64) and at the neuromuscular junction (156) in ALS
models, consistent with the concept that complement contributes
to nerve terminal destruction in ALS. In the TDP43Q331K mouse
model, progressive motor deficits, astrogliosis, and microgliosis
correlated with complement dysregulation in the spinal cord;
expression of C1qB, C4 and C3 was elevated and DAF mRNA
reduced in the lumbar spinal cord and in tibialis anterior
muscle of TDP43Q331K mice compared with controls (157).
Immunofluorescence confirmed markedly increased C1q and
C5aR1 in motor neurons and microglia.
Surprisingly, C1q deletion in SOD1G37R ALSmice exacerbated
synaptic loss at end-stage and it was implied that this was a
consequence of increased microglial phagocytosis; however, C1q
deletion did not significantly affect disease onset, progression, or
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survival and had no effect on global astrogliosis, microgliosis,
or neuronal loss (63) (Table 1). Deletion of the gene encoding
C4, which is necessary for activation of both the classical and
lectin pathways, significantly reduced the number of activated
macrophages found in sciatic nerves of mSOD1G93A mice but
again failed to influence the disease course (64). C3 deletion also
failed to affect overall survival or motor neuron loss in SOD1G93A
ALS mice (63); the finding that deletion of C3, central to all
complement pathways, fails to rescue disease has provoked the
suggestion that complement does not contribute to ALS disease
progression (at least in this model). The demonstration that
anti-complement drugs ameliorate disease in a similar model
contradicts this suggestion (Table 2). Oral administration of
C5aR1 antagonist PMX205, even when given in established
disease, reduced weight loss and motor deficit scores, slowed
disease progression and enhanced survival times in SOD1G93A
rats and mice (84, 85). These functional improvements were
associated with reduced astrocyte proliferation, reduced influx of
proinflammatory monocytes and granulocytes and an increase
in the CD4+: CD8+ T-cell ratio, consistent with the reported
neuroprotective role of CD4+-T cells in ALS (158). The same
authors showed that deficiency of C5aR1 (upregulated in human
and rodent ALS) extended survival in SOD1G93A mice (65).
Taken together, these data strongly implicate the C5a/C5aR1 axis
in disease and identify it as a target for therapy in ALS.
Huntington’s Disease (HD)
HD is an autosomal dominant, inherited neurodegenerative
disease characterized by progressive motor symptoms,
psychiatric disturbances, and dementia. It is caused by expansion
of a three-base-pair (CAG) repeat (39–121 repeats vs. normal
range 8–39 repeats) in exon 1 of the HTT gene that translates
into a polyglutamine tract at the N-terminus of the protein.
This results in a polyglutamine length-dependent misfolding
and accumulation of huntingtin protein in the striatum and
cortex (layers 3, 5, and 6) followed by neuronal loss in these areas
which spreads to the hippocampus (159, 160). Neuropathology
of HD is graded based on Vonsattel staging (161) dependent
on the severity of neuronal loss, astrogliosis, and brain atrophy.
Precisely how the huntingtin trinucleotide expansions result in
neuronal death and associated gliosis remain unclear. Microglial
activation can be demonstrated by PET scanning even in early
disease and correlates with disease severity (11C-raclopride
binding) (162); indeed, even in pre-symptomatic gene carriers,
microglial activation was present and correlated with striatal
neuronal dysfunction and with risk of developing HD within 5
years (163).
HD post-mortem tissue showed abundant reactive astrogliosis
and microgliosis and intranuclear ubiquitin positive inclusions
in the caudate and temporal lobes (164). IHC showed that
neurons, astrocytes and myelin sheaths in the HD caudate
and striatum were immunoreactive for C1q, C4, C3 and neo-
epitopes in iC3b and TCC (164). Expression of mRNA encoding
early complement components C1q (c-chain), C1r, C3, and
C4, complement regulators C1INH, Clusterin, MCP, DAF and
CD59, and complement receptors C3a and C5a was upregulated
in the HD striatum. Early disease stages did not stain for
complement suggesting that early neuronal damage precedes
local complement synthesis and activation. Microarray analysis
in HD post-mortem tissue demonstrated increased expression of
complement components C4A, C4B and C3, most significantly
in the most affected areas, caudate nucleus, and motor cortex
(165). Unbiased proteomic profiling revealed 18 proteins that
were differentially expressed in HD plasma, several of which are
involved in the innate immune system; Clusterin, C7 and C9
increased with disease severity (166).
Early animal models of HD utilized toxin-mediated
striatal lesions; for example, Lewis rats given intracerebral
3-nitropropionic acid (3-NP), an inhibitor of the mitochondrial
citric acid cycle, developed striatal lesions, weight loss, gait
disturbances, dystonia and ataxia, thus reproducing some
of the pathological and clinical characteristics of HD (86).
Oral administration of C5aR antagonist (PMX53 or PMX205)
reduced weight loss and motor deficits, even when given post-
toxin administration, whereas NSAID, ibuprofen, and a TNF-α
inhibitor (infliximab) had no significant functional impact,
suggesting that ability to rescue these deficits hinged on the
complement pathway per se rather than neuroinflammation in
general (Table 2). 3-NP treatment caused lesions with robust
neuronal death and neutrophil infiltration and surrounded by
C5aR-, C3-, and C9-positive glia. C5aR blockade reduced lesion
volume and number; lesions contained fewer apoptotic cells
and astrocytes and were no longer surrounded by complement-
positive glia. While these data were a helpful proof of concept
(and this was the first paper demonstrating that PMX53 and
PMX205 cross the BBB), the model used is extremely artificial,
acute and invasive, unlike the chronic, cumulative dysfunction
seen in HD.
R6/2 transgenic mice provide a more realistic HD model;
these mice express exon 1 of the human huntingtin gene,
including a pathological trinucleotide repeat; they develop
progressive behavioral and neuropathological deficits, including
synaptic loss, but do not develop neuronal loss and fail
to demonstrate upregulation of complement proteins (66).
It is, therefore, unsurprising that C3 deficiency did not
alter disease progression in this model. C5aR was the only
complement molecule upregulated in the model and it remains
undetermined whether targeting the C5a-C5aR1 axis would
be beneficial.
Parkinson’s Disease (PD)
PD is characterized by loss of dopaminergic neurons in the
substantia nigra and deposits of the protein α-synuclein that
form the pathological hallmarks of the disease, Lewy bodies.
Patients present with resting tremor, bradykinesia, and rigidity.
Complement activation has been associated with α-synuclein and
Lewy bodies in Parkinson’s disease; in vitro studies demonstrated
that the disease-associated splice variant α-synuclein 112, but
not the full length protein, cause activation of complement
(167). In vivo, C3d, C4d, C7 and C9 localization in Lewy
bodies was reported in one study (168), although this was not
recapitulated in a separate study (169). More recently, deposition
of iC3b and C9 in Lewy bodies and melanized neurons was
reported; iC3b immunoreactivity increased with normal ageing
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and was further elevated in PD vs. age-matched controls (170).
A correlation was described between the ratios of C3/Aβ42
or FH/Aβ42 in CSF and severity of Parkinson’s disease motor
and cognitive symptoms, but not with absolute levels of C3 or
FH (171).
Although there are many mouse models of PD, drug or
neurotoxin induced, or genetic, none fully replicates the human
disease (172). A few studies have explored roles of complement
in these models; absence of C3 in mice did not protect against
depletion of dopaminergic neurons in the toxin-induced MPTP
model (67) (Table 1). There was an increase of C1q in relevant
brain regions in this model but C1q deficiency did not protect
from disease (68). A very recent study identified a role for
CR3 in activation of the microglial NADPH oxidase (Nox2)
and subsequent neurodegeneration in a toxin-induced PD
model; CR3 knockout mice were protected from dopaminergic
neuron loss and motor dysfunction, suggesting that complement
opsonization and CR3 engagement contribute to the disease
process (69).
TARGETING COMPLEMENT IN
NEUROLOGICAL DISEASE
Getting Therapeutics Into the CNS
Having made the case above for an involvement of complement
in acute neurological injuries and neurodegenerative diseases,
attention naturally turns to therapeutic significance. There is
a huge and growing complement therapeutics industry with a
myriad of new drugs emerging; however, to date CNS targets
have been largely ignored (173). Drug delivery is a major limiting
factor for CNS therapies that needs to be considered when
designing therapeutics for treating neurological conditions. The
BBB precludes passive entry of molecules larger than ∼400 kDa
thus occluding entry of macromolecules, including antibody and
protein therapeutics. In TBI and SCI the BBB is impaired to
some degree, enabling drugs to access the injured areas (47).
Treatment options to access the CNS in diseases where the BBB
remains intact include both invasive and non-invasive techniques
[reviewed in (174, 175)]. Historically, access of drugs to the
CNS involved disruption or damage to the BBB or the use of
pharmacological agents to increase its permeability; however, in
many cases this resulted in widespread neuronal damage and
an associated inflammatory response. Less damaging ways of
opening the BBB include the use of focused ultrasound waves
of low intensity that cause local and temporary disruption to
the BBB and administration of “osmotic shock” agents (176).
Pharma companies have designed a host of other strategies
to deliver therapies, including Trojan horse delivery, use of
viral vectors, nanoparticles and chimeric peptides, expanded
on below.
Trojan horse technologies involve the creation of fusion
proteins that lock the drug to a delivery component that utilizes
receptors in the BBB, such as the insulin receptor and transferrin
receptor, to enable bidirectional transport into and out of the
brain. As an example of this concept, a recombinant anti-Aβ
single chain fV antibody (fragment variable region only) fused
to a fAb fragment of an anti-insulin receptor mAb bound the
insulin receptor at the BBB, was transcytosed across the barrier
enabling it to access and recognized Aβ within the brain and was
then shuttled out again with its Aβ cargo for disposal (177). Anti-
complement therapeutic antibodies, of which there are many in
the clinic or in development, could be similarly piggy-backed into
the brain to inhibit complement.
Small, hydrophobic molecules can cross the BBB via lipid-
mediated diffusion. As an example, oral administration of
the small molecule NLRP3 inhibitor MCC950 in PD mouse
models reduced nigrostriatal dopaminergic degeneration,
motor deficits and accumulation of α-synuclein through
inhibiting inflammasome activation (178). Several small-
molecule complement inhibitors are in development but,
with the exception of the anti-C5aR1 molecules PMX53 and
PMX205 described above, these have yet to be assessed for
BBB permeability.
Targeting Complement in CNS
Eculizumab, a humanized anti-C5 antibody, is the lead anti-
complement drug but to date has only been approved for two
rare disorders, paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS) and recently for
Myasthenia Gravis. In a recent small trial of eculizumab in NMO,
a demyelinating disease characterized by BBB disruption and
inflammation/degeneration of the optic nerve and spinal cord
(www.clinicaltrials.gov NCT00904826), treatment reduced the
number of neurological episodes (179). This study has raised
the prospect of using eculizumab for other inflammatory CNS
diseases, although the BBB is likely a much greater hurdle in
these other conditions and it is unclear whether they can be
treated systemically. There is an urgent need to apply rational
drug design for targeting complement activation in the CNS to
obtain effective treatments with low side-effects and costs; for
example, there is little point in designing an anti-C1q therapeutic
to be administered systemically for a CNS disease given that C1q
exists throughout the body and in the circulation at micromolar
levels—extremely high drug doses would be required to have
any impact at the desired site in the CNS even if the drug is
BBB penetrant. Given the ubiquitous expression of complement
proteins throughout the body and the role of complement
proteins in fighting infection and maintaining homeostasis,
anti-complement therapeutics at these doses would likely have
consequences throughout the body. Rather, therapies should
target areas of pathology, as described above for the fusion
proteins linking CR2 (localizes to C3 activation products in
tissues) with a complement regulator, or target complexes, for
example MAC, which exist at much lower concentrations and are
found only in areas of pathology.
A common stumbling block in designing treatments
for neuroinflammatory disorders is timing. Despite early
conceptions about the fixed nature of post-mitotic neurons
in the CNS, there is a great deal of redundancy and flexibility
in neuronal circuits. Networks are hence able to compensate
for a huge amount of cell loss through synaptic plasticity so
that, by the time patients present at the clinic with symptoms,
major neuronal death has already occurred. Inflammation as
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a cause and consequence of this neuronal death occurs early
and, unlike in acute conditions, fails to resolve because the
primary stimulus, cell death, accumulation of toxic proteins or
mitochondrial dysfunction, persists. Thus, effective treatments
that aim to halt or slow disease progression must be administered
early—likely before symptoms are apparent—and must prevent
further neuronal cell death and encourage resolution of
inflammation. Evidence from studies of the impact of NSAIDs
on neurodegeneration support the idea that early and long-term
treatment is protective but treatment post-onset fails (reviewed
by 106). Early intervention requires ways of identifying
those at high risk; genetic studies have identified polygenic
signals that include many inflammatory genes and are highly
predictive of risk of AD (106), and inflammatory biomarkers
may also help predict risk (114). For large scale screening of
pre-symptomatic populations expensive interventions such
as brain imaging or CSF sampling are not practicable; in
contrast, plasma offers an attractive source of biomarkers,
although the levels of inflammatory markers in plasma may not
reflect inflammation in the CNS. Simple and highly predictive
plasma biomarkers are emerging and are likely to transform
treatment of AD and other neurodegenerative diseases in the
near future (180).
With regard to anti-complement therapies, it is likely that
different approaches will be needed for different diseases;
identifying for each disease when complement is activated, which
pathways are activated and what the consequences are will be
essential for effective interventions. Studies to date have been
restricted to models and have focused on targeting the C3
convertases, central to all three activation pathways and thus a
blunt tool likely to impact immune defense and other beneficial
functions. The implication of C5a/C5aR in several CNS diseases
offers the prospect of more targeted therapy with less risk of
iatrogenic disease, although the systemic impact of long-term
inhibition of the C5a/C5aR axis are uncertain. Evidence from
models obtained either by complement gene deletion (Table 1)
or anti-complement therapies (Table 2) has been helpful but are
often contradictory, studies reporting both positive and negative
impacts in similar models; this likely results from differences in
timing and precise nature of the intervention and highlights once
again the need for a thorough understanding of the underpinning
biology prior to human studies.
CONCLUDING REMARKS
Therapy of acute neurological injury and neurodegenerative
diseases represent a major therapeutic challenge. Most of the
diseases described above currently have no effective therapies
and new approaches are desperately needed. Although there are
some common features, notably inflammation and complement
activation, the described diseases are very heterogeneous,
even within disease labels—AD is not a single disease!
Patient stratification, for example, selecting patients with high
inflammatory markers and evidence of ongoing complement
activation for anti-complement drug therapy, will be necessary
for successful trails in the future; this requires better biomarkers.
For most of the diseases, proof of concept for new approaches
to therapy is stymied by the lack of good models; critically,
agents that are effective in current models usually fail
in human trails (https://www.nature.com/articles/d41586-018-
05722-9). For AD, models that better reflect the human disease
are now available andmay help overcome this issue. Switching off
complement systemically will impact immune defense; while this
may not be an issue for short-term therapy in acute conditions,
in chronic diseases requiring life-long treatment it is a major
consideration. Despite all these problems, inflammation and
complement activation present tractable targets in neuroinjury
and neurodegenerative disease and deserve investment into
basic understanding and the development of CNS-targeting anti-
inflammatory and anti-complement drugs.
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